Bluebird announces FDA approval of gene therapy for rare blood disease

Bluebird announces FDA approval of gene therapy for rare blood disease
·1 min read

Shares of Buebird Bio Inc. jumped 12.1% in trading on Wednesday after the Food and Drug Administration approved the company's gene therapy as a treatment for beta‑thalassemia in some adult and pediatric patients. Beta-thalassemia is a rare, genetic blood disease, and the patients who qualify for the treatment require regular red blood cell transfusions. The one-time wholesale acquisition price for Zynteglo is $2.8 million. Bluebird also announced an outcomes-based agreement in which the company